SAN CARLOS, Calif., March 19 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that clinical data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) will be presented in a V-poster presentation at the American College of Cardiology (ACC) 56th Annual Scientific Session taking place in New Orleans, LA, March 24-27, 2007.
The presentation details are as follows: Date/Time: Monday, March 26, 2007, 12:00 - 1:00 p.m. CDT Presentation Number: 1202-252 Abstract Title: Safety and Tolerability of a Novel Tissue Factor/Factor VIIa Inhibitor rNAPc2 in Patients With Non-ST-Elevation Acute Coronary Syndrome Managed Invasively: Results From the ANTHEM/TIMI 32 Trial About V-Posters: V-posters are narrated by a prerecorded expert commentary and can be accessed by cell phone as attendees view the poster. The posters will remain on display for the entire length of the meeting. About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206, a preclinical candidate for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.
This press release contains “forward-looking statements” regarding the potential improvement or benefit that current and future clinical trial programs may demonstrate which statements are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; and clinical development processes. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo’s Annual Report on 10-K for the fiscal year ended December 31, 2006 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
Nuvelo, Inc.
CONTACT: Shelly Guyer, VP of Business Development & IR of Nuvelo, Inc.,+1-650-517-8437, sguyer@nuvelo.com; or Danielle Bertrand of WeissCommPartners, +1-415-946-1056, dbertrand@weiscommpartners.com, for Nuvelo, Inc.
Web site: http://www.nuvelo.com//
